UroGen Pharma(US:URGN)2026-03-02 16:00Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $109.8 million, a 21% increase from $90.4 million in 2024, driven by the commercial launch of Zusduri and increased sales of Jelmyto [18] - The net loss for 2025 was $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share in 2024 [21] - Cash equivalents and marketable securities totaled $120.5 million as of December 31, 2025 [21] Business Line Data and Key Metrics Changes - Zusduri generated $15.8 million in revenue for 2025, reflecting early launch dynamics [4] - Jelmyto generated net product revenue of $94 million for the full year 2025, indicating continued underlying demand growth [5][16] Market Data and Key Metrics Changes - As of December 31, 2025, there were 838 activated sites of care with 102 unique prescribers and 32 repeat prescribers for Zusduri [14] - Over 95% of covered lives had open access to Zusduri by year-end 2025 [14] Company Strategy and Development Direction - The primary focus is on the commercial launch of Zusduri, which addresses a large and underserved market, with potential peak revenue exceeding $1 billion [5] - The company is advancing its pipeline, including UGN-103 and UGN-104, with plans for NDA submissions and potential FDA approvals in 2026 and 2027 [6][11] - A refinancing agreement with Pharmakon Advisors has strengthened the balance sheet and enhanced financial flexibility [7][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early adoption of Zusduri, with positive feedback from prescribers and patients regarding its ease of use and clinical effectiveness [9][10] - The company anticipates that the conversion timeline from patient enrollment forms to dosing will improve as sites gain familiarity with the product [15] Other Important Information - The company is not providing formal sales guidance for Zusduri in 2026 due to its early launch stage but expects Jelmyto net product revenues to be in the range of $97 million to $101 million [23] - Full-year 2026 operating expenses are expected to be between $240 million and $250 million, driven by sales force expansion and lifecycle management plans [24] Q&A Session Summary Question: Insights on patient enrollment forms and potential guidance for Zusduri - Management indicated that they could consider providing formal guidance for Zusduri at least two quarters post the permanent J-code [28] - There has been a noticeable increase in key indicators since the J-code became effective, including new and repeat prescribers [30][31] Question: Trends in repeat prescribers and feedback from non-repeat prescribers - There is steady growth in both new and repeat prescribers, with positive experiences leading to increased confidence in reimbursement [36] Question: Lifecycle management and market introduction of UGN-103 - UGN-103 is expected to be introduced after obtaining a permanent J-code, with a potential launch in early 2028 [38] Question: Current use of Zusduri among different patient types - Zusduri is being used primarily for patients who recur early, have frequent recurrences, or are unfit for surgery, with enthusiasm from physicians regarding its clinical data [45][46] Question: Community versus academic center adoption of Zusduri - The utilization mix has shifted towards community settings, with approximately 50% of usage now in community practices [53][54]